ParkerVision (PRKR) 10-K 28 Mar 23 2022 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 24, 2023	Jun. 30, 2022
Document Information [Line Items]
Entity Central Index Key	0000914139
Entity Registrant Name	PARKERVISION INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity File Number	000-22904
Entity Incorporation, State or Country Code	FL
Entity Tax Identification Number	59-2971472
Entity Address, Address Line One	4446-1A Hendricks Avenue, Suite 354
Entity Address, City or Town	Jacksonville
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	32207
City Area Code	904
Local Phone Number	732-6100
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 11,187,709
Entity Common Stock, Shares Outstanding		84,522,832
Auditor Firm ID	569
Auditor Name	MSL, P.A
Auditor Location	Fort Lauderdale, Florida

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
CURRENT ASSETS:
Cash and cash equivalents	$ 109	$ 1,030
Prepaid expenses	244	574
Other current assets	30	25
Total current assets	383	1,629
Intangible assets, net	1,359	1,785
Operating lease right-of-use assets	4	7
Other assets, net	5	19
Total assets	1,751	3,440
CURRENT LIABILITIES:
Accounts payable	901	706
Accrued expenses:
Salaries and wages	23	27
Professional fees	79	109
Other accrued expenses	486	555
Related party note payable, current portion	139	94
Convertible notes, current portion	625	0
Operating lease liabilities, current portion	4	155
Total current liabilities	2,257	1,646
LONG-TERM LIABILITIES:
Secured contingent payment obligation	40,708	37,372
Unsecured contingent payment obligations	5,089	5,691
Convertible notes, net of current portion	3,913	2,895
Related party note payable, net of current portion	473	609
Operating lease liabilities, net of current portion	0	4
Total long-term liabilities	50,183	46,571
Total liabilities	52,440	48,217
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' DEFICIT:
Common stock, $.01 par value, 175,000 and 150,000 shares authorized, 81,246 and 76,992 issued and outstanding at December 31, 2022 and 2021, respectively	812	770
Additional paid-in capital	391,724	387,865
Accumulated deficit	(443,225)	(433,412)
Total shareholders' deficit	(50,689)	(44,777)
Total liabilities and shareholders' deficit	$ 1,751	$ 3,440

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares shares in Thousands	Dec. 31, 2022	Dec. 31, 2021
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	175,000	150,000
Common stock, shares issued (in shares)	81,246	76,992
Common stock, shares outstanding (in shares)	81,246	76,992

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Licensing revenue	$ 925	$ 144
Cost of sales	(10)	(5)
Gross margin	915	139
Selling, general, and administrative expenses	7,773	8,088
Total operating expenses	7,773	8,088
Interest and other income	103	242
Interest and other expense	(324)	(251)
Change in fair value of contingent payment obligations	(2,734)	(4,372)
Total interest and other	(2,955)	(4,381)
Net loss before income tax	(9,813)	(12,330)
Income tax expense	0	0
Net loss	(9,813)	(12,330)
Other comprehensive income, net of tax	0	0
Comprehensive loss	$ (9,813)	$ (12,330)
Basic and diluted net loss per common share (in dollars per share)	$ (0.13)	$ (0.17)
Weighted average common shares outstanding (in shares)	78,395	71,299

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Deficit - USD ($) $ in Thousands	Cumulative Effect, Period of Adoption, Adjustment [Member] Common Stock [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member] Additional Paid-in Capital [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member] Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Conversion and Payment of Interest-in-kind on Convertible Debt [Member] Common Stock [Member]	Conversion and Payment of Interest-in-kind on Convertible Debt [Member] Additional Paid-in Capital [Member]	Conversion and Payment of Interest-in-kind on Convertible Debt [Member] Retained Earnings [Member]	Conversion and Payment of Interest-in-kind on Convertible Debt [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2020	$ 0	$ (1,126)	$ 279	$ (847)					$ 586	$ 376,954	$ (421,361)	$ (43,821)
Issuance of common stock and warrants in public and private offerings, net of issuance costs and initial fair value of contingent payment rights									73	5,701	0	5,774
Issuance of common stock upon exercise of options and warrants									63	959	0	1,022
Issuance of common stock and warrants for services									9	863	0	872
Issuance of common stock upon conversion and payment of interest in kind on convertible debt					$ 37	$ 1,201	$ 0	$ 1,238
Share-based compensation, net of shares withheld for taxes									2	3,313	0	3,315
Net loss									0	0	(12,330)	(12,330)
Balance at Dec. 31, 2021									770	387,865	(433,412)	(44,777)
Issuance of common stock and warrants in public and private offerings, net of issuance costs and initial fair value of contingent payment rights									20	362	0	382
Issuance of common stock upon exercise of options and warrants									5	78	0	83
Issuance of common stock upon conversion and payment of interest in kind on convertible debt					$ 14	$ 282	$ 0	$ 296
Share-based compensation, net of shares withheld for taxes									1	3,080	0	3,081
Net loss									0	0	(9,813)	(9,813)
Issuance of common stock, warrants, and options for services									2	57	0	59
Balance at Dec. 31, 2022									$ 812	$ 391,724	$ (443,225)	$ (50,689)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (9,813)	$ (12,330)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	311	371
Share-based compensation	3,081	3,315
Change in fair value of contingent payment obligations	2,734	4,372
Loss on disposal/impairment of equipment and other assets	124	43
Loan forgiveness	0	(194)
Changes in operating assets and liabilities:
Prepaid expenses and other assets	396	784
Accounts payable and accrued expenses	363	(3,917)
Operating lease liabilities	(155)	(146)
Total adjustments	6,854	4,628
Net cash used in operating activities	(2,959)	(7,702)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(4)	(3)
Net cash used in investing activities	(4)	(3)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock, including contingent payment rights, in private offerings	382	6,186
Net proceeds from exercise of options and warrants	83	1,022
Net proceeds from debt financings	1,668	0
Debt repayments	(91)	(100)
Net cash provided by financing activities	2,042	7,108
NET CHANGE IN CASH AND CASH EQUIVALENTS	(921)	(597)
CASH AND CASH EQUIVALENTS, beginning of year	1,030	1,627
CASH AND CASH EQUIVALENTS, end of year	109	1,030
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	24	17
Cash paid for income taxes	$ 0	$ 0

Note 1 - Significant Accounting

Note 1 - Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1. SIGNIFICANT ACCOUNTING POLICIES ParkerVision, Inc. and its wholly-owned German subsidiary, ParkerVision GmbH (collectively “ParkerVision”, “we” or the “Company”) is in the business of innovating fundamental wireless hardware technologies and products. We have determined that our business currently operates under a single operating and reportable segment. We have designed and developed proprietary radio frequency (“RF”) technologies and integrated circuits based on those technologies, and we license our technologies to others for use in wireless communication products. We have expended significant financial and other resources to research and develop our RF technologies and to obtain patent protection for those technologies in the United States of America (“U.S.”) and certain foreign jurisdictions. We believe certain patents protecting our proprietary technologies have been broadly infringed by others, and therefore the primary focus of our business plan is the enforcement of our intellectual property rights through patent licensing and infringement litigation efforts. We currently have patent enforcement actions ongoing in various U.S. district courts against mobile handset, smart television and other WiFi product providers, as well as semiconductor suppliers for the infringement of a number of our RF patents. We have made significant investments in developing and protecting our technologies, the returns on which are dependent upon the generation of future revenues for realization. Basis of Presentation Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the U.S. (“GAAP”). Certain reclassifications have been made to prior period amounts to conform to the current period presentation. The consolidated financial statements include the accounts of ParkerVision, Inc. and our wholly-owned German subsidiary, ParkerVision GmbH, after elimination of all intercompany transactions and accounts. Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The more significant estimates made by us include projected future cash flows and risk-adjusted discount rates for estimating the fair value of our contingent payment obligations, the volatility and estimated lives of share-based awards used in the estimate of the fair market value of share-based compensation, the assessment of recoverability of long-lived assets, the amortization periods for intangible and long-lived assets, and the valuation allowance for deferred taxes. Actual results could differ from the estimates made. We periodically evaluate estimates used in the preparation of the financial statements for continued reasonableness. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation. Cash and Cash Equivalents We consider cash and cash equivalents to include cash on hand, interest-bearing deposits, overnight repurchase agreements and investments with original maturities of three Intangible Assets We capitalize outside legal costs and agency filing fees incurred in connection with securing the rights to our intellectual property. Patents, copyrights, and other intangible assets are amortized using the straight-line method over their estimated period of benefit. We estimate the economic lives of our patents and copyrights to be fifteen twenty may may Contingent Payment Obligations We have accounted for our secured and unsecured contingent payment obligations as long-term debt in accordance with Accounting Standards Codification (“ASC”) 470 10 25, 825, 3 11 Leases We have accounted for our finance and operating leases in accordance with ASC 842, 12 For operating leases with terms greater than 12 not twelve Finance leases are included in property and equipment and other accrued expenses on the consolidated balance sheets. Finance leases are recorded as an asset and an obligation at an amount equal to the present value of the minimum lease payments during the lease term. Amortization expense and interest expense associated with finance leases are included in selling, general, and administrative expense and interest expense, respectively, on the consolidated statements of comprehensive loss. Refer to Note 7 Convertible Debt We have issued debt that is convertible, at the holder’s option, into shares of our common stock at fixed conversion prices. Certain of the convertible notes were issued with conversion prices that were below market value of our common stock on the closing date resulting in a beneficial conversion feature which we recorded to equity with a corresponding discount to the debt that was amortized over the life of the notes as interest expense. Effective January 1, 2021, 2020 06 470 20 815 40 no December 15, 2023, December 15, 2020. Adoption of ASU 2020 06 Revenue Recognition We account for revenue under ASC 606, five 1 2 3 4 5 Our revenue is derived from patent licensing and settlement agreements. We have an active monitoring and enforcement program with respect to our intellectual property rights that includes seeking appropriate compensation from third may may Refer to Note 3 Cost of Sales Cost of sales includes amortization of intangible assets directly linked with revenue generating licensing activities. Amortization expense for intangible assets that are not Accounting for Share-Based Compensation We have various share-based compensation programs which provide for equity awards including stock options, restricted stock units (“RSUs”) and restricted stock awards (“RSAs”). We calculate the fair value of share-based equity awards on the date of grant and recognize the calculated fair value as compensation expense over the requisite service periods of the related awards. We estimate the fair value of stock option awards using the Black-Scholes option valuation model. This valuation model requires the use of highly subjective assumptions and estimates including how long employees will retain their stock options before exercising them and the volatility of our common stock price over the expected life of the equity award. Such estimates, and the basis for our conclusions regarding such estimates, are outlined in detail in Note 15. not Income Taxes The provision for income taxes is based on loss before taxes as reported in the accompanying consolidated statements of comprehensive loss. Deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established to reduce deferred tax assets when, based on available objective evidence, it is more likely than not not not not Loss per Common Share Basic loss per common share is determined based on the weighted-average number of common shares outstanding during each year. Diluted loss per common share is the same as basic loss per common share as all potential common shares are excluded from the calculation, as their effect is anti-dilutive. The number of shares underlying outstanding options, warrants, and convertible notes at December 31, 2022 2021 2022 2021 Options outstanding 24,380 23,215 Warrants outstanding 10,346 10,346 Shares underlying convertible notes 32,734 20,157 67,460 53,718 These potential shares were excluded from the computation of diluted loss per share as their effect would have been anti-dilutive.

Note 2 - Liquidity and Going Co

Note 2 - Liquidity and Going Concern	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. LIQUIDITY AND GOING CONCERN The accompanying consolidated financial statements as of and for the year ended December 31, 2022 one not We have incurred significant losses from operations and negative cash flows in every year since inception and have utilized the proceeds from the sales of our equity and equity-linked securities and our contingent funding arrangements with third December 31, 2022 December 31, 2022 one We had cash and cash equivalents of approximately $0.1 million at December 31, 2022 January 2023 ( 18 not twelve Our business plan is currently focused solely on our patent enforcement and technology licensing objectives. The timing and amount of proceeds from our patent enforcement actions are difficult to predict and there can be no 13 Significant portions of our litigation costs to date have been funded by contingent payment arrangements with legal counsel. Fee discounts offered by legal counsel in exchange for contingent payments upon successful outcome in our litigation are not In March 2023, 18 twelve one no The long-term continuation of our business plan is dependent upon our ability to secure sufficient financing to support our business, and our ability to generate revenues and/or patent-related proceeds sufficient to offset expenses and meet our contingent payment obligation and other long-term debt repayment obligations. Failure to generate sufficient revenues, raise additional capital through debt or equity financings, and/or reduce operating costs could have a material adverse effect on our ability to meet our short and long-term liquidity needs and achieve our intended long-term business objectives.

Note 3 - Revenue

Note 3 - Revenue	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	3. REVENUE During the years ended December 31, 2022 2021 no no no no December 31, 2022

Note 4 - Prepaid Expenses

Note 4 - Prepaid Expenses	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Prepaid Expenses [Text Block]	4. PREPAID EXPENSES Prepaid expenses consisted of the following at December 31, 2022 2021 2022 2021 Prepaid services $ 202 $ 523 Prepaid insurance 25 23 Prepaid licenses, software tools and support 15 16 Other prepaid expenses 2 12 $ 244 $ 574 Prepaid services at December 31, 2022 2021

Note 5 - Intangible Assets

Note 5 - Intangible Assets	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	5. INTANGIBLE ASSETS Intangible assets consisted of the following at December 31, 2022 2021 2022 2021 Patents and copyrights $ 14,319 $ 14,755 Less accumulated amortization (12,960 ) (12,970 ) $ 1,359 $ 1,785 Amortization expense for the years ended December 31, 2022 2021 December 31, 2022 2021 Future estimated amortization expense for intangible assets that have remaining unamortized amounts as of December 31, 2022 2023 $ 256 2024 243 2025 207 2026 140 2027 122 2028 and thereafter 391 Total $ 1,359

Note 6 - Accrued Liabilities

Note 6 - Accrued Liabilities	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. ACCRUED LIABILITIES Other accrued expenses consisted of the following at December 31, 2022 2021 2022 2021 Advances $ 425 $ 500 Accrued interest 56 28 Other accrued expenses 5 27 $ 486 $ 555 Advances include amounts received from litigation counsel as advanced reimbursement of out-of-pocket expenses expected to be incurred by us.

Note 7 - Leases

Note 7 - Leases	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	7. LEASES We lease our office and other facilities and certain office equipment under long-term, non-cancelable operating leases. No December 31, 2022 2021 2021. November 2022 Lease expense for operating leases is generally recognized on a straight-line basis over the lease term and is included in operating expenses on the consolidated statement of comprehensive loss. We recognized operating lease costs of $0.04 million for each of the years ended December 31, 2022 2021 December 31, 2022 2021 Supplemental Cash Flow Information The following table summarizes the supplemental cash flow information related to leases (in thousands): Year Ended Year Ended December 31, December 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 193 $ 181 Cash received for amounts included in the measurement of sublease assets: Operating cash flows from operating subleases 120 44 Other Information The table below summarizes other supplemental information related to leases: December 31, December 31, 2022 2021 Weighted-average remaining lease term (in years): Operating leases 0.8 0.9 Operating subleases - 0.9 Weighted average discount rate Operating leases (1) 16.2 % 12.2 % ( 1 Upon adoption of the new lease standard, discount rates used for existing leases were established at January 1, 2019. Undiscounted Cash Flows The future maturities of lease liabilities consist of the following as of December 31, 2022 Operating Leases 2023 $ 4 Thereafter - Total undiscounted lease payments 4 Less: imputed interest - Present value of lease liabilities 4 Less: current portion (4 ) Long-term lease obligations $ -

Note 8 - Notes Payable

Note 8 - Notes Payable	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Long-Term Debt [Text Block]	8. Notes Payable Note Payable to a Related Party We have an unsecured promissory note payable of $0.6 million to Sterne, Kessler, Goldstein, & Fox, PLLC (“SKGF”), a related party (see Note 16 April 30, 2027. December 31, 2022 2021 At December 31, 2022 2023 $ 139 2024 133 2025 139 2026 144 2027 57 Total $ 612 The estimated fair value of our notes payable at December 31, 2022

Note 9 - Convertible Notes

Note 9 - Convertible Notes	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Convertible Debt [Text Block]	9. Convertible Notes Our convertible notes represent five 2020 06 January 1, 2021, 1 We have the option to prepay the majority of the notes any time following the one two three four may For the year ended December 31, 2022 December 31, 2021 December 31, 2022 For the years ended December 31, 2022 2021 December 31, 2022 2021 In 2022 five August 22, 2022 ( No. 333 266777 January 2023, five 18 All of the shares underlying our convertible notes, including shares reserved for future in-kind interest payments on the notes, have been or will be registered for resale. Convertible notes payable at December 31, 2022 2021 Fixed Conversion Interest December 31, Description Rate Rate Maturity Date 2022 2021 Convertible notes dated September 10, 2018 $ 0.40 8.0 % September 7, 2023 $ 200 $ 200 Convertible notes dated September 19, 2018 $ 0.57 8.0 % September 19, 2023 425 425 Convertible notes dated February/March 2019 $ 0.25 8.0 % February 28, 2024 to March 13, 2024 750 750 Convertible notes dated June/July 2019 $ 0.10 8.0 % June 7, 2024 to July 15, 2024 295 320 Convertible notes dated July 18, 2019 $ 0.08 7.5 % July 18, 2024 700 700 Convertible notes dated September 13, 2019 $ 0.10 8.0 % September 13, 2024 50 50 Convertible notes dated January 8, 2020 $ 0.13 8.0 % January 8, 2025 1 450 450 Convertible notes dated May-August 2022 $ 0.13 8.0 % May 10, 2027 to August 3, 2027 1,668 - Total principal balance 4,538 2,895 Less current portion 625 - $ 3,913 $ 2,895 1 may one ten At December 31, 2022 2

Note 10 - Contingent Payment Ob

Note 10 - Contingent Payment Obligations	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Contingencies Disclosure [Text Block]	10. Contingent Payment Obligations Secured Contingent Payment Obligation The following table provides a reconciliation of our secured contingent payment obligation measured at estimated fair market value for the years ended December 31, 2022 2021 2022 2021 Secured contingent payment obligation, beginning of year $ 37,372 $ 33,057 Change in fair value 3,336 4,315 Secured contingent payment obligation, end of year $ 40,708 $ 37,372 Our secured contingent payment obligation represents the estimated fair value of our repayment obligation to Brickell Key Investments, LP (“Brickell”) under a February 2016 2022 2021. Brickell is entitled to priority payment of 100% of proceeds received by us, after reimbursement of out-of-pocket expenses and legal contingent fees, from all patent-related actions until such time that Brickell has been paid its remaining principal of approximately $14.7 million. Thereafter, Brickell is entitled to a significant portion of remaining proceeds from all patent-related actions until such time that Brickell has been repaid its minimum return. The minimum return is determined as a multiple of the funded amount that increases over time. The estimated minimum return due to Brickell was approximately $56.9 million and $48.8 million as of December 31, 2022 2021 Brickell holds a senior security interest in the majority of our assets until such time as the specified minimum return is paid, in which case, the security interest will be released except with respect to the patents and proceeds related to specific legal actions. The security interest is enforceable by Brickell in the event that we are in default under the agreement which would occur if (i) we fail, after notice, to pay proceeds to Brickell, (ii) we become insolvent or insolvency proceedings are commenced (and not not December 31, 2022 In addition, in the event of a change in control of the Company, Brickell has the right to be paid its return as defined under the CPIA based on the transaction price for the change in control event. We have elected to measure our secured contingent payment obligation at its estimated fair value based on probability-weighted estimated cash outflows, discounted back to present value using a discount rate determined in accordance with accepted valuation methods (see Note 11 Unsecured Contingent Payment Obligations The following table provides a reconciliation of our unsecured contingent payment obligations, measured at estimated fair market value, for the years ended December 31, 2022 2021 2022 2021 Unsecured contingent payment obligations, beginning of period $ 5,691 $ 5,222 Issuance of contingent payment rights - 412 Change in fair value (602 ) 57 Unsecured contingent payment obligations, end of period $ 5,089 $ 5,691  Our unsecured contingent payment obligations represent amounts payable to others from future patent-related proceeds including (i) a termination fee due to a litigation funder (“Termination Fee”) and (ii) contingent payment rights (“CPRs”) issued to accredited investors primarily in connection with equity financings. We have elected to measure these unsecured contingent payment obligations at their estimated fair value based on probability-weighted estimated cash outflows, discounted back to present value using a discount rate determined in accordance with accepted valuation methods. The unsecured contingent payment obligations will be remeasured to fair value at each reporting period with changes recorded in the consolidated statements of comprehensive loss until the contingency is resolved (see Note 11  The Termination Fee is a result of $1.0 million in advances received under a letter agreement with a third not March 31, 2020, five not March 31, 2020, December 31, 2022 The CPRs represent the estimated fair value of rights provided to accredited investors who purchased shares of our common stock in 2020 2021 third December 31, 2020. December 31, 2021 December 31, 2022 December 31, 2022

Note 11 - Fair Value Measuremen

Note 11 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Fair Value Disclosures [Text Block]	11. FAIR VALUE MEASUREMENTS ASC 820, three ● Level 1: ● Level 2: 1 ● Level 3: The following table summarizes financial assets and financial liabilities carried at fair value and measured on a recurring basis as of December 31, 2022 2021 Fair Value Measurements Total Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2022: Liabilities: Secured contingent payment obligation $ 40,708 $ - $ - $ 40,708 Unsecured contingent payment obligations 5,089 - - 5,089 December 31, 2021: Liabilities: Secured contingent payment obligation 37,372 - - 37,372 Unsecured contingent payment obligations 5,691 - - 5,691 For the years ended December 31, 2022 2021 no The fair values of our secured and unsecured contingent payment obligations were estimated using a probability-weighted income approach based on various cash flow scenarios as to the outcome of patent-related actions both in terms of timing and amount, discounted to present value using a risk-adjusted rate. We used a risk-adjusted discount rate of 18.41% at December 31, 2022 The following table provides quantitative information about the significant unobservable inputs used in the measurement of fair value for both the secured and unsecured contingent payment obligations at December 31, 2022 Secured Contingent Payment Obligation Unsecured Contingent Payment Obligations Unobservable Inputs Low Weighted Average High Low Weighted Average High Estimated undiscounted cash outflows (in millions) $ 0.0 $ 59.6 $ 88.4 $ 0.0 $ 7.5 $ 10.8 Duration (in years) 1.0 2.2 2.5 1.5 2.3 2.5 Estimated probabilities 5 % 17 % 35 % 5 % 18 % 35 % We evaluate the estimates and assumptions used in determining the fair value of our contingent payment obligations each reporting period and make any adjustments prospectively based on those evaluations. Changes in any of these Level 3

Note 12 - Income Taxes and Tax

Note 12 - Income Taxes and Tax Status	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Income Tax Disclosure [Text Block]	12. INCOME TAXES AND TAX STATUS Our net losses before income taxes for the years ended December 31, 2022 2021 No current or deferred tax provision or benefit was recorded in 2022 2021 A reconciliation between the provision for income taxes and the expected tax benefit using the federal statutory rate of 21% for each of the years ended December 31, 2022 2021 2022 2021 Tax benefit at statutory rate $ (2,061 ) $ (2,589 ) State tax benefit (422 ) (530 ) Increase in valuation allowance 2,416 3,368 Other 67 (249 ) $ - $ - Our deferred tax assets and liabilities relate to the following sources and differences between financial accounting and the tax bases of our assets and liabilities at December 31, 2022 2021 2022 2021 Gross deferred tax assets: Net operating loss carry-forward $ 75,470 $ 78,600 Research and development credit carry-forward 5,356 6,028 Stock compensation 1,127 356 Patents and other 1,482 1,470 Contingent payment obligations 7,033 6,341 Fixed assets (2 ) 53 Lease liabilities 1 38 90,467 92,886 Less valuation allowance (90,467 ) (92,886 ) - - Gross deferred tax liabilities: Convertible debt - - - - Net deferred tax asset $ - $ - Upon adoption of ASU 2020 06 January 1, 2021 ( 9 At December 31, 2022 2023 2037. December 31, 2022 2023 2038. Our ability to benefit from the tax credit carry-forwards could be limited under certain provisions of the Internal Revenue Code if there are ownership changes of more than 50%, 382 1986 382” 382, may 382, 50 three not December 31, 2022 382. Uncertain Tax Positions We file income tax returns in the U.S. federal jurisdiction, various state jurisdictions, and Germany. We have identified our Federal and Florida tax returns as our only major jurisdictions, as defined. The periods subject to examination for those returns are the 2003 2022 December 31, 2022 2021 2022 2021 Unrecognized tax benefits – beginning of year $ 653 $ 927 Reduction as a result of lapse of statute of limitations (15 ) (274 ) Unrecognized tax benefits – end of year $ 638 $ 653 Future changes in the unrecognized tax benefit will have no Our policy is that we recognize interest and penalties accrued on any unrecognized tax benefits as a component of our income tax expense. We do not December 31, 2022 2021 not

Note 13 - Commitments and Conti

Note 13 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	13. COMMITMENTS AND CONTINGENCIES Legal Proceedings From time to time, we are subject to legal proceedings and claims which arise in the ordinary course of our business. These proceedings include patent enforcement actions initiated by us against others for the infringement of our technologies, as well as proceedings brought by others against us at the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (“PTAB”) in an attempt to invalidate certain of our patent claims. The majority of our litigation, including our PTAB proceedings, is being paid for through contingency fee arrangements with our litigation counsel as well as third third ParkerVision v. Qualcomm (Middle District of Florida-Orlando Division) - Appealed to U.S. Court of Appeals for the Federal Circuit We have appealed certain March 2022 The patent infringement case was filed in the Middle District of Florida in May 2014. February 2016 6,091,940 ‘940 March 2017, sixth September 2018, ‘940 January 2019, July 2019, ‘940 may September 2019, ‘940 January 2020. In April 2020, 19, December 2020 May 2021. October 2020, December 2020; one January 2021. May 3, 2021 July 6, 2021. In March 2021, not November December 2021. Daubert May 2021. March 2021, 2020 July 2021, No. 7,865,177 ‘177 In January 2022, three March 9, 2022, one March 22, 2022, not three April 20, 2022, 30 ParkerVision v. Apple and Qualcomm (Middle District of Florida-Jacksonville Division) In December 2015, February 2016, July 2016, March 2017, May 2017. July 2017, July 2017, March 2018, March 2018 9,118,528 August 31, 2018. July 2019, August 2020. March 2020, 19, April 2020, ParkerVision v. LG (District of New Jersey) In July 2017, ParkerVision v. Apple and Qualcomm March 2018, ParkerVision v. Apple and Qualcomm ParkerVision v. Intel (Western District of Texas) In February 2020, May 2020 June 2020, one second ParkerVision v. Intel II June 2020 July 2020 September 2020, Inter Partes Review two January 2021, two Intel v. ParkerVision (PTAB) The court issued its claim construction ruling in January 2021 February 7, 2022. April 2021, two first June 2022. In January 2022, Intel v. ParkerVision (PTAB) February 2022, first six second one second two October 2022. March 2022, December 5, 2022. March 2022, May 2022, June 2022 December 5, 2022 February 6, 2023. Beginning in November 2022, January 2023. February 6, 2023 February 7, 2023, 18 ParkerVision v. Intel II (Western District of Texas) In June 2020, ParkerVision v. Intel second July 2020, January 2021, one July 2021, Intel v. ParkerVision (PTAB) 2021 June 2021 July 2021 October 2022. February 2022, Intel II six first none first one February 7, 2023, 18 Intel v. ParkerVision (PTAB) Intel filed IPR petitions against U.S. patent 7,539,474 ‘474 7,110,444 ‘444 ParkerVision v. Intel 8,190,108 ‘108 ParkerVision v. Intel II January 2021, ‘444 ‘474 November 1, 2021 ‘474 ‘444 January 2022. ‘444 seven ‘474 ‘444 ParkerVision v. Intel July 2022, '444 In July 2021, ‘108 October 2021 April 2022. June 2022 '108 ParkerVision v. Intel Additional Patent Infringement Cases Western District of Texas ParkerVision filed a number of additional patent cases in the Western District of Texas in 2020 ten May 2021, ten second June 2021 two second November 2022 two November 2022, four We dismissed the actions against Buffalo and Zyxel in 2021 November 2022, two The court has issued claim construction recommendations for the TCL and LGE cases, in which nearly all of the claim terms were decided in our favor. In November 2022, two two TCL, et. al. v. ParkerVision (PTAB) In January 2023, November 2022. February 2023, TCL, et. al. v. ParkerVision (PTAB) In May 2021, 7,292,835 ‘835 ‘444 November 2021, December 2021, two April 2022, September 2022. November 2022, November 2022,

Note 14 - Stock Authorization a

Note 14 - Stock Authorization and Issuance	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	14. STOCK AUTHORIZATION AND ISSUANCE Preferred Stock We have 15 million shares of preferred stock authorized for issuance at the direction of our board of directors (the “Board”). On November 17, 2005, December 31, 2022 Common Stock We have 175 million shares of common stock authorized for issuance as of December 31, 2022 September 2021 September 2022 As of December 31, 2022 Stock and Warrant Issuances Equity Based Financings The following table presents a summary of completed equity-based financing transactions for the years ended December 31, 2021 2022 Date Transaction # of Common Shares/ Units Sold Average Price per Share/ Unit # of Warrants Issued (in 000’s) Average Exercise Price per Warrant Net Proceeds (1) January 2021 Private placement of common stock with CPRs 2,976 $ 0.35 - - $ 1,040 March 2021 Private placement of common stock with warrants 3,231 $ 1.29 1,619 $ 1.75 $ 4,156 December 2021 Private placement of common stock with warrants 1,053 $ 0.95 526 $ 1.00 $ 1,000 November 2022 Private placement of common stock 1,000 $ 0.20 - - $ 200 December 2022 Private placement of common stock 1,000 $ 0.20 - - $ 200 ( 1 After deduction of applicable offering costs. Net proceeds are inclusive of the value of the CPRs that are classified as long-term debt (see Note 10 Private Placements In January 2021, 10 April 26, 2021 ( No. 333 255217 In March 2021, March 2026. April 26, 2021 ( No. 333 255217 In December 2021, December 2026. January 24, 2022 ( No. 333 262147 In November December 2022, April 7, 2023 April 30, 2023 ( June 30, 2023). Stock and Warrant Issuances Payment for Services In October 2022, December 2024. 2020 March 2023 March 2026. On May 22, 2020, July 14, 2020, October 30, 2020, January 12, 2021 April 6, 2021 December 31, 2021 December 31, 2022 June 2021, twelve August 2022, six not On October 30, 2020, third twelve 10 April 2021, December 31, 2021. On November 22, 2022, third twelve four three November 22, 2022 three In addition, from time to time, we issue restricted stock awards under our approved equity plans to third December 31, 2021, 2019 15 Common Stock Warrants We had outstanding warrants for the purchase of up to 10.3 million shares of our common stock as of December 31, 2022 2021 December 31, 2022 Shareholder Protection Rights Agreement On November 20, 2020, second November 21, 2005, November 20, 2020 November 20, 2023 The Rights Agreement provided for the issuance, on November 29, 2005, not not The rights initially are not may may may may not one ten may December 31, 2022

Note 15 - Share-based Compensat

Note 15 - Share-based Compensation	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	15. SHARE-BASED COMPENSATION For the years ended December 31, 2022 2021 third 4 As of December 31, 2022 Stock Incentive Plans 2019 We adopted a long-term incentive equity plan in August 2019 January 2021, not “2019 2019 2019 may not December 31, 2022 2019 2019 January 2023 ( 18 2011 We adopted a long-term incentive equity plan in September 2011 2014, 2016 2017, not “2011 2011 2011 no may December 31, 2022 2011 January 2023, 2011 2008 We adopted an equity incentive plan in August 2008 ( “2008 2008 not 2008 2008 no may December 31, 2022 2008 In January 2023, 2008 Restricted Stock Awards RSAs are issued as executive and employee incentive compensation and as payment for services to others. The value of the award is based on the closing price of our common stock on the date of grant. RSAs are generally immediately vested. Restricted Stock Units RSUs are issued as incentive compensation to executives, employees, and non-employee directors. Each RSU represents a right to one not one three one RSAs and RSUs The following table presents a summary of RSA and RSU activity under the 2008, 2011, 2019 December 31, 2022 Non-vested Shares Shares Weighted-Average Non-vested at beginning of year - Granted 166 0.18 Vested (166 ) 0.18 Forfeited - - Non-vested at end of year - $ - The total fair value of RSAs and RSUs vested under the Stock Plans for the years ended December 31, 2022 2021 Stock Options Stock options are issued as incentive compensation to executives, employees, consultants and non-employee directors. Stock options are generally granted with exercise prices at or above fair market value of the underlying shares at the date of grant. Fair market value of the underlying shares is determined based on observable market prices at the date of the grant. The fair value of options granted is estimated using the Black-Scholes option pricing model. Generally, fair value is determined as of the grant date. Options for employees, including executives and non-employee directors, are generally granted under the Stock Plans. The following table presents a summary of option activity under the Stock Plans for the year ended December 31, 2022 Shares Weighted- Average Exercise Price Weighted-Average Remaining Contractual Term (in years) Aggregate Intrinsic Value ($) Outstanding at beginning of year 23,215 $ 0.42 Granted 1,450 0.19 Exercised (485 ) 0.17 Forfeited/Expired - - Outstanding at end of year 24,180 0.41 3.6 $ 542 Vested at end of year 22,943 $ 0.42 3.3 $ 489 The weighted average per share fair value of options granted during the years ended December 31, 2022 2021 December 31, 2022 2021 The fair value of option grants under the Stock Plans for the years ended December 31, 2022 2021 Year ended December 31, 2022 2021 Expected option term (in years) 1 5 4 Expected volatility factor 2 143.9 - 155.9% 141.1% Risk-free interest rate 3 3.05 - 4.09% 0.36% Expected annual dividend yield 0% 0% 1 2 3 Options by Price Range The options outstanding at December 31, 2022 Options Outstanding Options Vested Range of Exercise Prices Number Outstanding at December 31, 2022 Wtd. Avg. Exercise Price Wtd. Avg. Remaining Contractual Life Number Exercisable at December 31, 2022 Wtd. Avg. Exercise Price Wtd. Avg. Remaining Contractual Life $0.171 - $0.33 10,254 $ 0.18 4.5 9,017 $ 0.18 3.7 $0.50 - $0.75 13,553 0.54 3.0 13,553 0.54 3.0 $1.98 - $2.97 373 2.02 1.5 373 2.02 1.5 24,180 $ 0.41 3.6 22,943 $ 0.42 3.3 We issue new shares of our common stock upon exercise of options or vesting of RSUs or RSAs under the Stock Plans. The shares underlying the Stock Plans are registered. Cash received from option exercises for the years ended December 31, 2022 2021

Note 16 - Related Party Transac

Note 16 - Related Party Transactions	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	16. RELATED PARTY TRANSACTIONS We paid approximately $0.01 million and $0.1 million in 2022 2021 one September 2006, 2022 2021 8 December 31, 2022 In May 2022, one December 2016. December 31, 2022 In August 2022, October 2022. January 2023, 18

Note 17 - Concentration of Cred

Note 17 - Concentration of Credit Risk	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	17. CONCENTRATIONS OF CREDIT RISK Financial instruments that potentially subject us to a concentration of credit risk principally consist of cash and cash equivalents. Cash and cash equivalents are primarily held in bank accounts and overnight investments. At times our cash balances on deposit with banks may

Note 18 - Subsequent Events

Note 18 - Subsequent Events	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	18. SUBSEQUENT EVENTS In February 2023, March 2023, In February 2023, two 13 In January 2023, five may ten one may January 2023, April 7, 2023 April 30, 2023 ( June 30, 2023). On January 16, 2023, 2019 2019

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the U.S. (“GAAP”). Certain reclassifications have been made to prior period amounts to conform to the current period presentation. The consolidated financial statements include the accounts of ParkerVision, Inc. and our wholly-owned German subsidiary, ParkerVision GmbH, after elimination of all intercompany transactions and accounts.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The more significant estimates made by us include projected future cash flows and risk-adjusted discount rates for estimating the fair value of our contingent payment obligations, the volatility and estimated lives of share-based awards used in the estimate of the fair market value of share-based compensation, the assessment of recoverability of long-lived assets, the amortization periods for intangible and long-lived assets, and the valuation allowance for deferred taxes. Actual results could differ from the estimates made. We periodically evaluate estimates used in the preparation of the financial statements for continued reasonableness. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents We consider cash and cash equivalents to include cash on hand, interest-bearing deposits, overnight repurchase agreements and investments with original maturities of three
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Intangible Assets We capitalize outside legal costs and agency filing fees incurred in connection with securing the rights to our intellectual property. Patents, copyrights, and other intangible assets are amortized using the straight-line method over their estimated period of benefit. We estimate the economic lives of our patents and copyrights to be fifteen twenty may may
Contingent Payment Obligations [Policy Text Block]	Contingent Payment Obligations We have accounted for our secured and unsecured contingent payment obligations as long-term debt in accordance with Accounting Standards Codification (“ASC”) 470 10 25, 825, 3 11
Lessee, Leases [Policy Text Block]	Leases We have accounted for our finance and operating leases in accordance with ASC 842, 12 For operating leases with terms greater than 12 not twelve Finance leases are included in property and equipment and other accrued expenses on the consolidated balance sheets. Finance leases are recorded as an asset and an obligation at an amount equal to the present value of the minimum lease payments during the lease term. Amortization expense and interest expense associated with finance leases are included in selling, general, and administrative expense and interest expense, respectively, on the consolidated statements of comprehensive loss. Refer to Note 7
Debt, Policy [Policy Text Block]	Convertible Debt We have issued debt that is convertible, at the holder’s option, into shares of our common stock at fixed conversion prices. Certain of the convertible notes were issued with conversion prices that were below market value of our common stock on the closing date resulting in a beneficial conversion feature which we recorded to equity with a corresponding discount to the debt that was amortized over the life of the notes as interest expense. Effective January 1, 2021, 2020 06 470 20 815 40 no December 15, 2023, December 15, 2020. Adoption of ASU 2020 06
Revenue [Policy Text Block]	Revenue Recognition We account for revenue under ASC 606, five 1 2 3 4 5 Our revenue is derived from patent licensing and settlement agreements. We have an active monitoring and enforcement program with respect to our intellectual property rights that includes seeking appropriate compensation from third may may Refer to Note 3
Cost of Goods and Service [Policy Text Block]	Cost of Sales Cost of sales includes amortization of intangible assets directly linked with revenue generating licensing activities. Amortization expense for intangible assets that are not
Share-Based Payment Arrangement [Policy Text Block]	Accounting for Share-Based Compensation We have various share-based compensation programs which provide for equity awards including stock options, restricted stock units (“RSUs”) and restricted stock awards (“RSAs”). We calculate the fair value of share-based equity awards on the date of grant and recognize the calculated fair value as compensation expense over the requisite service periods of the related awards. We estimate the fair value of stock option awards using the Black-Scholes option valuation model. This valuation model requires the use of highly subjective assumptions and estimates including how long employees will retain their stock options before exercising them and the volatility of our common stock price over the expected life of the equity award. Such estimates, and the basis for our conclusions regarding such estimates, are outlined in detail in Note 15. not
Income Tax, Policy [Policy Text Block]	Income Taxes The provision for income taxes is based on loss before taxes as reported in the accompanying consolidated statements of comprehensive loss. Deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established to reduce deferred tax assets when, based on available objective evidence, it is more likely than not not not not
Earnings Per Share, Policy [Policy Text Block]	Loss per Common Share Basic loss per common share is determined based on the weighted-average number of common shares outstanding during each year. Diluted loss per common share is the same as basic loss per common share as all potential common shares are excluded from the calculation, as their effect is anti-dilutive. The number of shares underlying outstanding options, warrants, and convertible notes at December 31, 2022 2021 2022 2021 Options outstanding 24,380 23,215 Warrants outstanding 10,346 10,346 Shares underlying convertible notes 32,734 20,157 67,460 53,718 These potential shares were excluded from the computation of diluted loss per share as their effect would have been anti-dilutive.

Note 1 - Significant Accounti_2

Note 1 - Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	2022 2021 Options outstanding 24,380 23,215 Warrants outstanding 10,346 10,346 Shares underlying convertible notes 32,734 20,157 67,460 53,718

Note 4 - Prepaid Expenses (Tabl

Note 4 - Prepaid Expenses (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	2022 2021 Prepaid services $ 202 $ 523 Prepaid insurance 25 23 Prepaid licenses, software tools and support 15 16 Other prepaid expenses 2 12 $ 244 $ 574

Note 5 - Intangible Assets (Tab

Note 5 - Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	2022 2021 Patents and copyrights $ 14,319 $ 14,755 Less accumulated amortization (12,960 ) (12,970 ) $ 1,359 $ 1,785
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	2023 $ 256 2024 243 2025 207 2026 140 2027 122 2028 and thereafter 391 Total $ 1,359

Note 6 - Accrued Liabilities (T

Note 6 - Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	2022 2021 Advances $ 425 $ 500 Accrued interest 56 28 Other accrued expenses 5 27 $ 486 $ 555

Note 7 - Leases (Tables)

Note 7 - Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Lessee, Operating Lease, Supplemental Cash Flow Information [Table Text Block]	Year Ended Year Ended December 31, December 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 193 $ 181 Cash received for amounts included in the measurement of sublease assets: Operating cash flows from operating subleases 120 44
Lease, Cost [Table Text Block]	December 31, December 31, 2022 2021 Weighted-average remaining lease term (in years): Operating leases 0.8 0.9 Operating subleases - 0.9 Weighted average discount rate Operating leases (1) 16.2 % 12.2 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Operating Leases 2023 $ 4 Thereafter - Total undiscounted lease payments 4 Less: imputed interest - Present value of lease liabilities 4 Less: current portion (4 ) Long-term lease obligations $ -

Note 8 - Notes Payable (Tables)

Note 8 - Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Maturities of Long-Term Debt [Table Text Block]	2023 $ 139 2024 133 2025 139 2026 144 2027 57 Total $ 612

Note 9 - Convertible Notes (Tab

Note 9 - Convertible Notes (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Convertible Debt [Table Text Block]	Fixed Conversion Interest December 31, Description Rate Rate Maturity Date 2022 2021 Convertible notes dated September 10, 2018 $ 0.40 8.0 % September 7, 2023 $ 200 $ 200 Convertible notes dated September 19, 2018 $ 0.57 8.0 % September 19, 2023 425 425 Convertible notes dated February/March 2019 $ 0.25 8.0 % February 28, 2024 to March 13, 2024 750 750 Convertible notes dated June/July 2019 $ 0.10 8.0 % June 7, 2024 to July 15, 2024 295 320 Convertible notes dated July 18, 2019 $ 0.08 7.5 % July 18, 2024 700 700 Convertible notes dated September 13, 2019 $ 0.10 8.0 % September 13, 2024 50 50 Convertible notes dated January 8, 2020 $ 0.13 8.0 % January 8, 2025 1 450 450 Convertible notes dated May-August 2022 $ 0.13 8.0 % May 10, 2027 to August 3, 2027 1,668 - Total principal balance 4,538 2,895 Less current portion 625 - $ 3,913 $ 2,895

Note 10 - Contingent Payment _2

Note 10 - Contingent Payment Obligations (Tables)	12 Months Ended
	Dec. 31, 2022
Unsecured Debt [Member]
Notes Tables
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]	2022 2021 Unsecured contingent payment obligations, beginning of period $ 5,691 $ 5,222 Issuance of contingent payment rights - 412 Change in fair value (602 ) 57 Unsecured contingent payment obligations, end of period $ 5,089 $ 5,691
Secured Debt [Member]
Notes Tables
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]	2022 2021 Secured contingent payment obligation, beginning of year $ 37,372 $ 33,057 Change in fair value 3,336 4,315 Secured contingent payment obligation, end of year $ 40,708 $ 37,372

Note 11 - Fair Value Measurem_2

Note 11 - Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	Fair Value Measurements Total Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2022: Liabilities: Secured contingent payment obligation $ 40,708 $ - $ - $ 40,708 Unsecured contingent payment obligations 5,089 - - 5,089 December 31, 2021: Liabilities: Secured contingent payment obligation 37,372 - - 37,372 Unsecured contingent payment obligations 5,691 - - 5,691
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Secured Contingent Payment Obligation Unsecured Contingent Payment Obligations Unobservable Inputs Low Weighted Average High Low Weighted Average High Estimated undiscounted cash outflows (in millions) $ 0.0 $ 59.6 $ 88.4 $ 0.0 $ 7.5 $ 10.8 Duration (in years) 1.0 2.2 2.5 1.5 2.3 2.5 Estimated probabilities 5 % 17 % 35 % 5 % 18 % 35 %

Note 12 - Income Taxes and Ta_2

Note 12 - Income Taxes and Tax Status (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2022 2021 Tax benefit at statutory rate $ (2,061 ) $ (2,589 ) State tax benefit (422 ) (530 ) Increase in valuation allowance 2,416 3,368 Other 67 (249 ) $ - $ -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2022 2021 Gross deferred tax assets: Net operating loss carry-forward $ 75,470 $ 78,600 Research and development credit carry-forward 5,356 6,028 Stock compensation 1,127 356 Patents and other 1,482 1,470 Contingent payment obligations 7,033 6,341 Fixed assets (2 ) 53 Lease liabilities 1 38 90,467 92,886 Less valuation allowance (90,467 ) (92,886 ) - - Gross deferred tax liabilities: Convertible debt - - - - Net deferred tax asset $ - $ -
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	2022 2021 Unrecognized tax benefits – beginning of year $ 653 $ 927 Reduction as a result of lapse of statute of limitations (15 ) (274 ) Unrecognized tax benefits – end of year $ 638 $ 653

Note 14 - Stock Authorization_2

Note 14 - Stock Authorization and Issuance (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Summary of Equity Offerings [Table Text Block]	Date Transaction # of Common Shares/ Units Sold Average Price per Share/ Unit # of Warrants Issued (in 000’s) Average Exercise Price per Warrant Net Proceeds (1) January 2021 Private placement of common stock with CPRs 2,976 $ 0.35 - - $ 1,040 March 2021 Private placement of common stock with warrants 3,231 $ 1.29 1,619 $ 1.75 $ 4,156 December 2021 Private placement of common stock with warrants 1,053 $ 0.95 526 $ 1.00 $ 1,000 November 2022 Private placement of common stock 1,000 $ 0.20 - - $ 200 December 2022 Private placement of common stock 1,000 $ 0.20 - - $ 200

Note 15 - Share-based Compens_2

Note 15 - Share-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	Non-vested Shares Shares Weighted-Average Non-vested at beginning of year - Granted 166 0.18 Vested (166 ) 0.18 Forfeited - - Non-vested at end of year - $ -
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Shares Weighted- Average Exercise Price Weighted-Average Remaining Contractual Term (in years) Aggregate Intrinsic Value ($) Outstanding at beginning of year 23,215 $ 0.42 Granted 1,450 0.19 Exercised (485 ) 0.17 Forfeited/Expired - - Outstanding at end of year 24,180 0.41 3.6 $ 542 Vested at end of year 22,943 $ 0.42 3.3 $ 489
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year ended December 31, 2022 2021 Expected option term (in years) 1 5 4 Expected volatility factor 2 143.9 - 155.9% 141.1% Risk-free interest rate 3 3.05 - 4.09% 0.36% Expected annual dividend yield 0% 0%
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Options Outstanding Options Vested Range of Exercise Prices Number Outstanding at December 31, 2022 Wtd. Avg. Exercise Price Wtd. Avg. Remaining Contractual Life Number Exercisable at December 31, 2022 Wtd. Avg. Exercise Price Wtd. Avg. Remaining Contractual Life $0.171 - $0.33 10,254 $ 0.18 4.5 9,017 $ 0.18 3.7 $0.50 - $0.75 13,553 0.54 3.0 13,553 0.54 3.0 $1.98 - $2.97 373 2.02 1.5 373 2.02 1.5 24,180 $ 0.41 3.6 22,943 $ 0.42 3.3

Note 1 - Significant Accounti_3

Note 1 - Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Long-Term Debt, Total	$ 612
Additional Paid in Capital, Total	391,724	$ 387,865
Retained Earnings (Accumulated Deficit), Total	(443,225)	$ (433,412)
Accounting Standards Update 2020-06 [Member]
Long-Term Debt, Total	800
Additional Paid in Capital, Total	1,100
Retained Earnings (Accumulated Deficit), Total	$ 300
Intellectual Property [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	15 years
Intellectual Property [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	20 years

Note 1 - Significant Accounti_4

Note 1 - Significant Accounting Policies - Schedule of Antidilutive Securities Excluded From Earnings Per Share (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Antidilutive securities (in shares)	67,460	53,718
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	24,380	23,215
Warrant [Member]
Antidilutive securities (in shares)	10,346	10,346
Convertible Debt Securities [Member]
Antidilutive securities (in shares)	32,734	20,157

Note 2 - Liquidity and Going _2

Note 2 - Liquidity and Going Concern (Details Textual) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Mar. 28, 2023	Jan. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Net Income (Loss) Attributable to Parent, Total			$ (9,813)	$ (12,330)
Net Cash Provided by (Used in) Operating Activities, Total			(2,959)	(7,702)
Retained Earnings (Accumulated Deficit), Total			(443,225)	(433,412)
Cash and Cash Equivalents, at Carrying Value, Total			$ 109	$ 1,030
Subsequent Event [Member]
Proceeds from Issuance of Debt and Equity		$ 800
Proceeds from Patent License and Settlement Agreement	$ 25,000

Note 3 - Revenue (Details Textu

Note 3 - Revenue (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Contract with Customer, Liability, Revenue Recognized	$ 930	$ 140
Contract with Customer, Liability, Total	0
Contract with Customer, Asset, before Allowance for Credit Loss	$ 0

Note 4 - Prepaid Expenses (Deta

Note 4 - Prepaid Expenses (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Prepaid Services	$ 202	$ 523
Pre Paid Consulting Services [Member]
Prepaid Services	$ 200	$ 500

Note 4 - Prepaid Expenses - Pre

Note 4 - Prepaid Expenses - Prepaid Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Prepaid services	$ 202	$ 523
Prepaid insurance	25	23
Prepaid licenses, software tools and support	15	16
Other prepaid expenses	2	12
Prepaid Expense, Current, Total	$ 244	$ 574

Note 5 - Intangible Assets (Det

Note 5 - Intangible Assets (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Amortization of Intangible Assets	$ 300	$ 350
Gain (Loss) on Disposition of Intangible Assets	$ (100)	$ (30)

Note 5 - Intangible Assets - In

Note 5 - Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Patents and copyrights	$ 14,319	$ 14,755
Less accumulated amortization	(12,960)	(12,970)
Total	$ 1,359	$ 1,785

Note 5 - Intangible Assets - Sc

Note 5 - Intangible Assets - Schedule of Finite Lived Intangible Assets, Future Amortization Expense (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
2023	$ 256
2024	243
2025	207
2026	140
2027	122
2028 and thereafter	391
Total	$ 1,359	$ 1,785

Note 6 - Accrued Liabilities -

Note 6 - Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Advances	$ 425	$ 500
Accrued interest	56	28
Other accrued expenses	5	27
Accrued Liabilities, Total	$ 486	$ 555

Note 7 - Leases (Details Textua

Note 7 - Leases (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating Lease, Cost	$ 40	$ 40
Interest and Other Income [Member]
Rental Income, Nonoperating	$ 110	$ 50

Note 7 - Leases - Supplemental

Note 7 - Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating cash flows from operating leases	$ 193	$ 181
Operating cash flows from operating subleases	$ 120	$ 44

Note 7 - Leases - Operating Lea

Note 7 - Leases - Operating Lease, Lease Cost (Details)		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2022
Operating leases (Year)		10 months 24 days	9 months 18 days
Operating subleases (Year)		10 months 24 days
Operating leases (1)	[1]	12.20%	16.20%
[1]Upon adoption of the new lease standard, discount rates used for existing leases were established at January 1, 2019.

Note 7 - Leases - Lessee Operat

Note 7 - Leases - Lessee Operating Lease Liability Maturity (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
2023	$ 4
Thereafter	0
Total undiscounted lease payments	4
Less: imputed interest	0
Present value of lease liabilities	4
Less: current portion	(4)	$ (155)
Operating lease liabilities, net of current portion	$ 0	$ 4

Note 8 - Notes Payable (Details

Note 8 - Notes Payable (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Convertible Debt [Member]
Debt Instrument, Interest Rate, Stated Percentage	12%
Interest Expense, Debt, Total	$ 300,000	$ 260,000
Notes Payable, Fair Value Disclosure	470,000
Promissory Notes [Member] | Unsecured Debt [Member] | Sterne Kessler Goldstein Fox Pllc [Member]
Debt Instrument, Face Amount	$ 600,000
Debt Instrument, Interest Rate, Stated Percentage	4%
Debt Instrument, Periodic Payment, Total	$ 12,500
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid	20,000
Interest Expense, Debt, Total	$ 30,000	$ 30,000

Note 8 - Notes Payable - Schedu

Note 8 - Notes Payable - Schedule of Maturities of Long-Term Debt (Details) $ in Thousands	Dec. 31, 2022 USD ($)
2023	$ 139
2024	133
2025	139
2026	144
2027	57
Total	$ 612

Note 9 - Convertible Notes (Det

Note 9 - Convertible Notes (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Convertible Debt [Member]
Debt Instrument, Term (Year)		5 years
Debt Instrument, Interest Rate, Stated Percentage		12%
Debt Conversion, Converted Instrument, Amount		$ 30	$ 970
Debt Conversion, Converted Instrument, Shares Issued (in shares)		300,000	3,400,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 0.10	$ 0.29
Debt Instrument, Convertible, Number of Equity Instruments		32,700,000
Interest Expense, Debt, Total		$ 300	$ 260
Notes Payable, Fair Value Disclosure		470
Convertible Debt [Member] | Fair Value, Inputs, Level 2 [Member]
Notes Payable, Fair Value Disclosure		$ 3,400
Convertible Debt [Member] | Subsequent Event [Member]
Debt Instrument, Term (Year)	5 years
Debt Instrument, Interest Rate, Stated Percentage	9%
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 0.16
Proceeds from Convertible Debt	$ 700
Convertible Debt [Member] | Five-year Convertible Promissory Notes [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 0.13
Debt Instrument, Face Amount		$ 1,700
Convertible Debt [Member] | Conversion and Payment of Interest-in-kind on Convertible Debt [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)		1,203,000	272,000
Convertible Debt [Member] | Debt Instrument, Redemption, Period One [Member]
Debt Instrument, Redemption Price, Percentage		25%
Convertible Debt [Member] | Debt Instrument, Redemption, Period Two [Member]
Debt Instrument, Redemption Price, Percentage		20%
Convertible Debt [Member] | Debt Instrument, Redemption, Period Three [Member]
Debt Instrument, Redemption Price, Percentage		15%
Convertible Debt [Member] | Debt Instrument, Redemption, Period Four [Member]
Debt Instrument, Redemption Price, Percentage		10%
Convertible Debt [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]
Debt Instrument, Convertible, Beneficial Conversion Feature				$ 800
Convertible Notes Dated E [Member]
Debt Instrument, Interest Rate, Stated Percentage		2%

Note 9 - Convertible Notes - Sc

Note 9 - Convertible Notes - Schedule Of Convertible Notes Payable (Details) - USD ($) $ / shares in Units, $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Convertible Debt, Total	$ 4,538	$ 2,895
Less current portion	625	0
Convertible Debt, Noncurrent	$ 3,913	2,895
Convertible Notes dated September 10, 2018 [Member]
Fixed Conversion Rate (in dollars per share)	$ 0.40
Effective Interest Rate	8%
Convertible Debt, Total	$ 200	200
Convertible Note Dated September 19, 2018 [Member]
Fixed Conversion Rate (in dollars per share)	$ 0.57
Effective Interest Rate	8%
Convertible Debt, Total	$ 425	425
Convertible Notes Dated February/March 2019 [Member]
Fixed Conversion Rate (in dollars per share)	$ 0.25
Effective Interest Rate	8%
Convertible Debt, Total	$ 750	750
Convertible Notes Dated June/July 2019 [Member]
Fixed Conversion Rate (in dollars per share)	$ 0.10
Effective Interest Rate	8%
Convertible Debt, Total	$ 295	320
Convertible Notes Dated July 18, 2019 [Member]
Fixed Conversion Rate (in dollars per share)	$ 0.08
Effective Interest Rate	7.50%
Convertible Debt, Total	$ 700	700
Convertible Notes Dated September 13, 2019 [Member]
Fixed Conversion Rate (in dollars per share)	$ 0.10
Effective Interest Rate	8%
Convertible Debt, Total	$ 50	50
Convertible Notes Dated January 8, 2020 [Member]
Fixed Conversion Rate (in dollars per share)	$ 0.13
Effective Interest Rate	8%
Convertible Debt, Total	$ 450	450
Convertible Notes Dated May-August 2022 [Member]
Fixed Conversion Rate (in dollars per share)	$ 0.13
Effective Interest Rate	8%
Convertible Debt, Total	$ 1,668	$ 0

Note 10 - Contingent Payment _3

Note 10 - Contingent Payment Obligations (Details Textual) - USD ($) $ in Thousands	12 Months Ended		24 Months Ended	83 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2022	Mar. 31, 2020
Repayments of Debt				$ 3,300
Contingent Payment Obligation, Remaining Principal Amount	$ 14,700			14,700
Contingent Payment Obligation, Minimum Return	56,900	$ 48,800		56,900
Common Stock With Contingent Payment Rights [Member]
Proceeds from Issuance of Common Stock	0	1,100
Contingent Payment Rights [Member]
Proceeds from Issuance of Common Stock		$ 400
Maximum Amount of Net Proceeds Recoverable	10,000			10,000
Amount Investors' Subscription is Divided By	10,000			10,000
Aggregate Proceeds From Contingent Payment Rights	5,800			5,800
Termination Fee [Member] | Unsecured Debt [Member]
Advances From Funder			$ 1,000
Loss Contingency, Estimate of Possible Loss	$ 2,400			2,400	$ 5,000
Contingent Payment Obligation [Member] | Minimum [Member]
Proceeds From Patent-Related Actions, Percent	100%
Contingent Payment Rights [Member] | Unsecured Debt [Member]
Debt Instrument, Fair Value Disclosure, Total	$ 2,700			2,700
Brickell [Member]
Proceeds from Issuance of Debt	$ 0			$ 18,000

Note 10 - Contingent Payment _4

Note 10 - Contingent Payment Obligations - Reconciliation Of Secured Contingent Obligation At Fair Value (Details) - Contingent Payment Obligation [Member] - Secured Debt [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Secured contingent payment obligation, beginning of year	$ 37,372	$ 33,057
Change in fair value	3,336	4,315
Secured contingent payment obligation, end of year	$ 40,708	$ 37,372

Note 10 - Contingent Payment _5

Note 10 - Contingent Payment Obligations - Reconciliation Of Unsecured Contingent Obligation At Fair Value (Details) - Unsecured Debt [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Secured contingent payment obligation, beginning of year	$ 5,691	$ 5,222
Issuance of contingent payment rights	0	412
Change in fair value	(602)	57
Secured contingent payment obligation, end of year	$ 5,089	$ 5,691

Note 11 - Fair Value Measurem_3

Note 11 - Fair Value Measurements (Details Textual) - Secured Debt [Member]	Dec. 31, 2022
Measurement Input, Discount Rate [Member]
Debt Instrument, Measurement Input	0.1841
Measurement Input, Risk Free Interest Rate [Member]
Debt Instrument, Measurement Input	0.0441
Measurement Input, Entity Credit Risk [Member]
Debt Instrument, Measurement Input	0.08
Litigation Inherent Risk [Member]
Debt Instrument, Measurement Input	0.06

Note 11 - Fair Value Measurem_4

Note 11 - Fair Value Measurements - Schedule Of Assets And Liabilities Measured At Fair Value On A Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Secured Contingent Payment Obligation [Member]
Liabilities	$ 40,708	$ 37,372
Secured Contingent Payment Obligation [Member] | Fair Value, Inputs, Level 1 [Member]
Liabilities	0	0
Secured Contingent Payment Obligation [Member] | Fair Value, Inputs, Level 2 [Member]
Liabilities	0	0
Secured Contingent Payment Obligation [Member] | Fair Value, Inputs, Level 3 [Member]
Liabilities	40,708	37,372
Unsecured Contingent Payment Obligation [Member]
Liabilities	5,089	5,691
Unsecured Contingent Payment Obligation [Member] | Fair Value, Inputs, Level 1 [Member]
Liabilities	0	0
Unsecured Contingent Payment Obligation [Member] | Fair Value, Inputs, Level 2 [Member]
Liabilities	0	0
Unsecured Contingent Payment Obligation [Member] | Fair Value, Inputs, Level 3 [Member]
Liabilities	$ 5,089	$ 5,691

Note 11 - Fair Value Measurem_5

Note 11 - Fair Value Measurements - Quantitative Information (Details) - Fair Value, Inputs, Level 3 [Member]	Dec. 31, 2022 USD ($) yr
Estimated Undiscounted Cash Outflows [Member] | Secured Debt [Member] | Minimum [Member]
Measurement input | $	0
Estimated Undiscounted Cash Outflows [Member] | Secured Debt [Member] | Weighted Average [Member]
Measurement input | $	59,600
Estimated Undiscounted Cash Outflows [Member] | Secured Debt [Member] | Maximum [Member]
Measurement input | $	88,400
Estimated Undiscounted Cash Outflows [Member] | Unsecured Debt [Member] | Minimum [Member]
Measurement input | $	0
Estimated Undiscounted Cash Outflows [Member] | Unsecured Debt [Member] | Weighted Average [Member]
Measurement input | $	7,500
Estimated Undiscounted Cash Outflows [Member] | Unsecured Debt [Member] | Maximum [Member]
Measurement input | $	10,800
Measurement Input, Expected Term [Member] | Secured Debt [Member] | Minimum [Member]
Measurement input | yr	1
Measurement Input, Expected Term [Member] | Secured Debt [Member] | Weighted Average [Member]
Measurement input | yr	2.2
Measurement Input, Expected Term [Member] | Secured Debt [Member] | Maximum [Member]
Measurement input | yr	2.5
Measurement Input, Expected Term [Member] | Unsecured Debt [Member] | Minimum [Member]
Measurement input | yr	1.5
Measurement Input, Expected Term [Member] | Unsecured Debt [Member] | Weighted Average [Member]
Measurement input | yr	2.3
Measurement Input, Expected Term [Member] | Unsecured Debt [Member] | Maximum [Member]
Measurement input | yr	2.5
Estimated Probabilities [Member] | Secured Debt [Member] | Minimum [Member]
Measurement input	0.05
Estimated Probabilities [Member] | Secured Debt [Member] | Weighted Average [Member]
Measurement input	0.17
Estimated Probabilities [Member] | Secured Debt [Member] | Maximum [Member]
Measurement input	0.35
Estimated Probabilities [Member] | Unsecured Debt [Member] | Minimum [Member]
Measurement input	0.05
Estimated Probabilities [Member] | Unsecured Debt [Member] | Weighted Average [Member]
Measurement input	0.18
Estimated Probabilities [Member] | Unsecured Debt [Member] | Maximum [Member]
Measurement input	0.35

Note 12 - Income Taxes and Ta_3

Note 12 - Income Taxes and Tax Status (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Current Income Tax Expense (Benefit), Total	$ 0
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21%
Operating Loss Carryforwards	$ 300,800
Operating Loss Carryforwards, Subject To Expiration	$ 260,100
Open Tax Year	2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	$ 5,400

Note 12 - Income Taxes and Ta_4

Note 12 - Income Taxes and Tax Status - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Tax benefit at statutory rate	$ (2,061)	$ (2,589)
State tax benefit	(422)	(530)
Increase in valuation allowance	2,416	3,368
Other	$ 67	$ (249)

Note 12 - Income Taxes and Ta_5

Note 12 - Income Taxes and Tax Status - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Net operating loss carry-forward	$ 75,470	$ 78,600
Research and development credit carry-forward	5,356	6,028
Stock compensation	1,127	356
Patents and other	1,482	1,470
Contingent payment obligations	7,033	6,341
Fixed assets, tax liability	(2)
Fixed assets, tax asset		53
Lease liabilities	1	38
Deferred Tax Assets, Gross, Total	90,467	92,886
Less valuation allowance	(90,467)	(92,886)
Convertible debt	0	0
Net deferred tax asset	$ 0	$ 0

Note 12 - Income Taxes and Ta_6

Note 12 - Income Taxes and Tax Status - Schedule of Unrecognized Tax Beneifts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Unrecognized tax benefits – beginning of year	$ 653	$ 927
Reduction as a result of lapse of statute of limitations	(15)	(274)
Unrecognized tax benefits – end of year	$ 638	$ 653

Note 13 - Commitments and Con_2

Note 13 - Commitments and Contingencies (Details Textual) $ in Billions	1 Months Ended
	Jan. 31, 2022	Jul. 31, 2020	May 31, 2020	Apr. 30, 2020 USD ($)	Feb. 29, 2020	Jul. 31, 2019	Mar. 31, 2018	Jul. 31, 2017	Mar. 31, 2017	Dec. 31, 2015
Parkervision V. Qualcomm Middle District Of Florida [Member]
Gain Contingency, Patents Found Infringed upon, Number									3
Gain Contingency, Patents Allegedly Infringed upon, Number									6
Loss Contingency, Patents Split Decision, Number									2
Loss Contingency, Patents Allegedly Infringed, Seeking Invalidation, Number									4
Claim Construction, Number				7
Gain Contingency Damages Sought				$ 1.3
Parkervision V. Qualcomm Middle District Of Florida [Member] | Maximum [Member]
Claim Construction, Number				10
Parkervision V. Apple and Qualcomm Middle District of Florida [Member]
Gain Contingency, Patents Allegedly Infringed upon, Number							4			4
Claim Construction, Number						2
Loss Contingency, Patents Number, Motion To Dismiss							3
Parkervision V. Apple and Qualcomm Middle District of Florida [Member] | Maximum [Member]
Claim Construction, Number						6
Parkervision V. LG Electronics [Member]
Gain Contingency, Patents Allegedly Infringed upon, Number								4
Parkervision V. Intel Western District Of Texas [Member]
Gain Contingency, Patents Allegedly Infringed upon, Number			2		8
Number of Asserted Patents	6
Parkervision V. Intel Ii Western District Of Texas [Member]
Gain Contingency, Patents Allegedly Infringed upon, Number		2
Additional Number Of Patent Subject To Inter Parter Review		2

Note 14 - Stock Authorization_3

Note 14 - Stock Authorization and Issuance (Details Textual) - USD ($) $ / shares in Units, $ in Thousands					1 Months Ended											2 Months Ended	12 Months Ended		83 Months Ended
	Nov. 22, 2022	Oct. 30, 2020	Jul. 14, 2020	Nov. 21, 2005	Dec. 31, 2022		Nov. 30, 2022		Oct. 31, 2022	Jun. 30, 2022	Dec. 31, 2021		Jun. 30, 2021	Mar. 31, 2021	Jan. 31, 2021	Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Sep. 16, 2022	Sep. 30, 2021	Nov. 20, 2020	Jul. 31, 2020	Nov. 17, 2005
Preferred Stock, Shares Authorized (in shares)					15,000,000											15,000,000	15,000,000		15,000,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)					0											0	0		0
Common Stock, Shares Authorized (in shares)					175,000,000						150,000,000					175,000,000	175,000,000	150,000,000	175,000,000	175,000,000	150,000,000		140,000,000
Repayments of Debt																			$ 3,300
Class of Warrant or Right, Outstanding (in shares)					10,300,000											10,300,000	10,300,000		10,300,000
Stock Issued During Period, Value, Issued for Services																	$ 59
Class of Warrant or Right, Weighted Average Remaining Life (Year)																	2 years 1 month 6 days
Estimate of Fair Value Measurement [Member] | Additional Paid-in Capital [Member]
Warrants and Rights Outstanding					$ 3,200											$ 3,200	$ 3,200		$ 3,200
Third Party Providing Consulting Services [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	200,000
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)	$ 0.21
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Value	$ 30
Intro Act [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)			50,000							150,000			100,000
Stock Issued During Period, Value, Issued for Services										$ 30			$ 120				$ 100	$ 50
Securities Purchase Agreements [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)		70,000																35,000
Stock Issued During Period, Value, Issued for Services		$ 20																$ 40
Securities Purchase Agreements [Member] | Contingent Payment Rights [Member]
Unsecured Debt, Total		20
Debt Instrument, Fair Value Disclosure, Total		$ 100
Warrants With Extended Expiration Dates [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)									$ 1
Class of Warrant or Right, Outstanding (in shares)									200,000
Fair Value Adjustment of Warrants									$ 20
Shareholder Protection Rights Agreement [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)					0											0	0		0
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 14.50																		$ 8.54
Protection Rights, Separate from Common Stock after Acquisition of Outstanding Shares, Threshold Percentage				15%
Preferred Stock, Redemption Price Per Share (in dollars per share)				$ 0.01
Weighted Average [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 0.75											$ 0.75	$ 0.75		$ 0.75
Private Placement With Contingent Purchase Rights [Member]
Stock Issued During Period, Shares, New Issues (in shares)							1,000,000				1,053,000				2,976,430
Shares Issued, Price Per Share (in dollars per share)							$ 0.20				$ 0.95				$ 0.35			$ 0.95
Stock Issued During Period, Value, New Issues							$ 200	[1]			$ 1,000	[1]			$ 1,000
Issuance of Warrants, Number (in shares)							0				526,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$ 0				$ 1							1
Contingent Payment Obligation [Member]
Proceeds from Issuance of Common Stock															$ 400
Private Placement With Warrants [Member]
Stock Issued During Period, Shares, New Issues (in shares)					1,000,000						1,052,631			3,230,942
Shares Issued, Price Per Share (in dollars per share)					$ 0.20						$ 0.95			$ 1.29		0.20	0.20	0.95	0.20
Stock Issued During Period, Value, New Issues					$ 200	[1]					$ 1,000			$ 4,200
Issuance of Warrants, Number (in shares)					0						526,315			1,619,289
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 0						$ 1			$ 1.75		$ 0	0	$ 1	0
Securities Purchase Agreements [Member]
Stock Issued During Period, Shares, New Issues (in shares)																2,000,000
Shares Issued, Price Per Share (in dollars per share)					$ 0.20											$ 0.20	$ 0.20		$ 0.20
Stock Issued During Period, Value, New Issues																$ 400
Liquidated Damages Percentage																1%
Liquidated Damages Amount																$ 20
Securities Purchase Agreements [Member] | Maximum [Member]
Liquidated Damages Percentage																6%
Shareholder Approved Equity Compensation Plans [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)					360,000											360,000	360,000		360,000
Convertible Debt [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)					32,700,000											32,700,000	32,700,000		32,700,000
Conversion and Payment of Interest-in-kind on Convertible Debt [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)					2,000,000											2,000,000	2,000,000		2,000,000
Secured Debt [Member] | Private Placement With Warrants [Member] | Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. [Member]
Repayments of Debt														$ 3,000
Warrants and Options [member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)					34,700,000											34,700,000	34,700,000		34,700,000
Restricted Stock [Member] | Long Term Incentive Plan 2019 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)																	217,143
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested																	$ 300
Series E Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)																								100,000
[1]After deduction of applicable offering costs. Net proceeds are inclusive of the value of the CPRs that are classified as long-term debt (see Note 10).

Note 14 - Stock Authorization_4

Note 14 - Stock Authorization and Issuance - Summary of Equity Offerings (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended
		Dec. 31, 2022		Nov. 30, 2022		Dec. 31, 2021		Mar. 31, 2021	Jan. 31, 2021
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)									2,976,000
Shares Issued, Price Per Share (in dollars per share)									$ 0.35
Number of warrants issued (in shares)									0
Average exercise price per warrant (in dollars per share)									$ 0
Stock Issued During Period, Value, New Issues	[1]								$ 1,040
Private Placement and Amendment To Add Contingent Purchase Rights [Member]
Stock Issued During Period, Shares, New Issues (in shares)								3,231,000
Shares Issued, Price Per Share (in dollars per share)								$ 1.29
Number of warrants issued (in shares)								1,619,000
Average exercise price per warrant (in dollars per share)								$ 1.75
Stock Issued During Period, Value, New Issues	[1]							$ 4,156
Private Placement With Contingent Purchase Rights [Member]
Stock Issued During Period, Shares, New Issues (in shares)				1,000,000		1,053,000			2,976,430
Shares Issued, Price Per Share (in dollars per share)				$ 0.20		$ 0.95			$ 0.35
Number of warrants issued (in shares)				0		526,000
Average exercise price per warrant (in dollars per share)				$ 0		$ 1
Stock Issued During Period, Value, New Issues				$ 200	[1]	$ 1,000	[1]		$ 1,000
Private Placement With Warrants [Member]
Stock Issued During Period, Shares, New Issues (in shares)		1,000,000				1,052,631		3,230,942
Shares Issued, Price Per Share (in dollars per share)		$ 0.20				$ 0.95		$ 1.29
Number of warrants issued (in shares)		0				526,315		1,619,289
Average exercise price per warrant (in dollars per share)		$ 0				$ 1		$ 1.75
Stock Issued During Period, Value, New Issues		$ 200	[1]			$ 1,000		$ 4,200
[1]After deduction of applicable offering costs. Net proceeds are inclusive of the value of the CPRs that are classified as long-term debt (see Note 10).

Note 15 - Share-based Compens_3

Note 15 - Share-based Compensation (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Jan. 31, 2021
Share-Based Payment Arrangement, Expense	$ 3,100,000	$ 3,300,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 200,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	1 year 3 months 18 days
Restricted Stock Units (RSUs) [Member] | Non Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	1 year
Restricted Stock Units (RSUs) [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	1 year
Restricted Stock Units (RSUs) [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	3 years
Restricted Stock Awards and Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$ 30,000	$ 600,000
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)	$ 0.17	$ 0.46
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value	$ 3,000,000	$ 3,400,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 100,000	$ 300,000
Long Term Incentive Plan 2019 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)	27,000,000		27,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee (in shares)		1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee, Value		$ 175,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	281,467
Long Term Incentive Equity Plan 2011 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)	3,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee (in shares)	150,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	61,302
The 2008 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)	50,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee (in shares)	5,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	20,473

Note 15 - Share-Based Compens_4

Note 15 - Share-Based Compensation - Schedule of Share-Based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) - Restricted Stock Awards and Restricted Stock Units (RSUs) [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Non-vested, shares (in shares)	0
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	166
Granted, grant date fair value (in dollars per share) | $ / shares	$ 0.18
Vested, shares (in shares)	(166)
Vested, grant date fair value (in dollars per share) | $ / shares	$ 0.18
Forfeited, shares (in shares)	0
Forfeited, grant date fair value (in dollars per share) | $ / shares	$ 0
Non-vested, shares (in shares)	0
Non-vested, grant date fair value (in dollars per share) | $ / shares	$ 0

Note 15 - Share-Based Compens_5

Note 15 - Share-Based Compensation - Share-Based Compensation, Stock Options Activity (Details) - Share-Based Payment Arrangement, Option [Member] $ / shares in Units, shares in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares
Outstanding, shares (in shares) | shares	23,215
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 0.42
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | shares	1,450
Granted, weighted average exercise price (in dollars per share) | $ / shares	$ 0.19
Exercised, shares (in shares) | shares	(485)
Exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 0.17
Forfeited/Expired, shares (in shares) | shares	0
Forfeited/Expired, weighted average exercise price (in dollars per share) | $ / shares	$ 0
Outstanding, shares (in shares) | shares	24,180
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 0.41
Outstanding, weighted average remaining contractual term (Year)	3 years 7 months 6 days
Outstanding, aggregate intrinsic value | $	$ 542
Vested, shares (in shares) | shares	22,943
Vested, weighted average exercise price (in dollars per share) | $ / shares	$ 0.42
Vested, weighted average remaining contractual term (Year)	3 years 3 months 18 days
Vested, aggregate intrinsic value | $	$ 489

Note 15 - Share-Based Compens_6

Note 15 - Share-Based Compensation - Schedule of Share-Based Payment Award Stock Options, Valuation Assumptions (Details) - Share-Based Payment Arrangement, Option [Member]		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021
Expected option term (in years) 1 (Year)	[1]	5 years	4 years
Expected volatility factor 2	[2]		141.10%
Risk-free interest rate 3	[3]		0.36%
Expected annual dividend yield		0%	0%
Minimum [Member]
Expected volatility factor 2	[2]	143.90%
Risk-free interest rate 3	[3]	3.05%
Maximum [Member]
Expected volatility factor 2	[2]	155.90%
Risk-free interest rate 3	[3]	4.09%
[1]The expected term was generally determined based on historical activity for grants with similar terms and for similar groups of employees and represents the period of time that options are expected to be outstanding. For employee options, groups of employees with similar historical exercise behavior are considered separately for valuation purposes.[2]The stock volatility for each grant is measured using the weighted average of historical daily price changes of our common stock over the most recent period equal to the expected option life of the grant.[3]The risk-free interest rate for periods equal to the expected term of the share option is based on the U.S. Treasury yield curve in effect at the measurement date.

Note 15 - Share-based Compens_7

Note 15 - Share-based Compensation - Schedule of Share Based Compensation, Shares Authorized Under Stock Option Plans By Exercise Price Range (Details)	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Options outstanding, number (in shares) | shares	24,180
Options outstanding, weighted average exercise price (in dollars per share)	$ 0.41
Options outstanding, weighted average contractual life (Year)	3 years 7 months 6 days
Options vested, number (in shares) | shares	22,943
Options vested, weighted average exercise price (in dollars per share)	$ 0.42
Options vested, weighted average contractual life (Year)	3 years 3 months 18 days
Exercise Price Range One [Member]
Exercise price, lower limit (in dollars per share)	$ 0.171
Exercise price, upper limit (in dollars per share)	$ 0.33
Options outstanding, number (in shares) | shares	10,254
Options outstanding, weighted average exercise price (in dollars per share)	$ 0.18
Options outstanding, weighted average contractual life (Year)	4 years 6 months
Options vested, number (in shares) | shares	9,017
Options vested, weighted average exercise price (in dollars per share)	$ 0.18
Options vested, weighted average contractual life (Year)	3 years 8 months 12 days
Exercise Price Range Two [Member]
Exercise price, lower limit (in dollars per share)	$ 0.50
Exercise price, upper limit (in dollars per share)	$ 0.75
Options outstanding, number (in shares) | shares	13,553
Options outstanding, weighted average exercise price (in dollars per share)	$ 0.54
Options outstanding, weighted average contractual life (Year)	3 years
Options vested, number (in shares) | shares	13,553
Options vested, weighted average exercise price (in dollars per share)	$ 0.54
Options vested, weighted average contractual life (Year)	3 years
Exercise Price Range Three [Member]
Exercise price, lower limit (in dollars per share)	$ 1.98
Exercise price, upper limit (in dollars per share)	$ 2.97
Options outstanding, number (in shares) | shares	373
Options outstanding, weighted average exercise price (in dollars per share)	$ 2.02
Options outstanding, weighted average contractual life (Year)	1 year 6 months
Options vested, number (in shares) | shares	373
Options vested, weighted average exercise price (in dollars per share)	$ 2.02
Options vested, weighted average contractual life (Year)	1 year 6 months

Note 16 - Related Party Trans_2

Note 16 - Related Party Transactions (Details Textual) $ / shares in Units, Pure in Thousands, $ in Thousands	1 Months Ended		12 Months Ended
	Jan. 31, 2023 $ / shares shares	Aug. 30, 2022 USD ($) $ / shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	May 31, 2022 USD ($) $ / shares
Convertible Debt, Total			$ 4,538	$ 2,895
Subsequent Event [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares	$ 0.16
Sterne Kessler Goldstein Fox Pllc [Member] | Patent-Related Legal Services [Member]
Related Party Transaction, Expenses from Transactions with Related Party			10	100
Sterne Kessler Goldstein Fox Pllc [Member] | Promissory Note [Member] | Unsecured Debt [Member]
Related Party Transaction, Expenses from Transactions with Related Party			100	$ 100
Notes Payable, Related Parties			600
Paul Rosenbaum [Member] | Promissory Notes [Member]
Debt Instrument, Face Amount					$ 100
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares					$ 0.13
Convertible Debt, Total			$ 200
Debt Instrument, Convertible, Number of Equity Instruments			1,020
Sanford Litvack [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares	62,500
Shares Issued, Price Per Share (in dollars per share) | $ / shares	$ 0.16
Sanford Litvack [Member] | Promissory Notes [Member]
Debt Instrument, Face Amount		$ 30
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares		$ 0.13
Debt Instrument, Convertible, Number of Equity Instruments		200

Note 18 - Subsequent Events (De

Note 18 - Subsequent Events (Details Textual) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	1 Months Ended		12 Months Ended
	Mar. 28, 2023	Jan. 31, 2023	Dec. 31, 2022	Jan. 16, 2023	Dec. 31, 2021	Jan. 31, 2021
Long Term Incentive Plan 2019 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)			27			27
Convertible Debt [Member]
Debt Instrument, Term (Year)			5 years
Debt Instrument, Convertible, Conversion Price (in dollars per share)			$ 0.10		$ 0.29
Debt Instrument, Interest Rate, Stated Percentage			12%
Subsequent Event [Member]
Proceeds from Patent License and Settlement Agreement	$ 25,000
Proceeds from Issuance of Common Stock		$ 140
Shares Issued, Price Per Share (in dollars per share)		$ 0.16
Liquidated Damages Percentage		1%
Liquidated Damages Amount		$ 50
Subsequent Event [Member] | Long Term Incentive Plan 2019 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)				30
Subsequent Event [Member] | Maximum [Member]
Liquidated Damages Percentage		6%
Subsequent Event [Member] | Convertible Debt [Member]
Proceeds from Convertible Debt		$ 700
Debt Instrument, Term (Year)		5 years
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 0.16
Debt Instrument, Renewal Term (Year)		10 years
Debt Instrument, Interest Rate, Stated Percentage		9%
Subsequent Event [Member] | Convertible Debt [Member] | Portion of Convertible Debt With Renewable Maturity Date [Member]
Debt Instrument, Face Amount		$ 500